The ABHD6 Knockout Ca Ski Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Ca Ski human cervical carcinoma cell line, engineered to disrupt the ABHD6 gene. This loss-of-function model abolishes ABHD6-mediated monoacylglycerol lipase activity, providing a powerful tool for investigating lipid signaling in HPV-driven carcinogenesis. The polyclonal population retains genetic heterogeneity, representing a realistic pool of knockout variants for functional studies without clonal selection bias.
Ca Ski cells are an established epithelial cell line derived from a cervical squamous cell carcinoma and stably harbor integrated human papillomavirus type 16 (HPV16) genomes. They serve as a widely used model for HPV16-positive cervical cancer, exhibiting key oncogenic features such as expression of viral E6 and E7 oncoproteins and deregulated cell cycle control. This host background is particularly relevant for dissecting the interplay between endocannabinoid signaling and HPV-mediated transformation.
ABHD6 encodes a membrane-associated serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG), a major endocannabinoid, into arachidonic acid and glycerol. By terminating 2-AG signaling, ABHD6 modulates activation of cannabinoid receptors CB1 and CB2. It operates alongside monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH) in the endocannabinoid system. Disruption of ABHD6 is predicted to elevate 2-AG levels, enhancing cannabinoid receptor-dependent signaling pathways that regulate proliferation, migration, and apoptosis.
In the Ca Ski cervical carcinoma context, ABHD6 knockout provides a unique opportunity to explore how increased 2-AG tone influences HPV16-positive tumor cell behavior. Given the emerging roles of cannabinoid receptors in cancer cell growth and immune modulation, this model can be used to assess whether ABHD6 loss alters tumorigenic properties through CB1/CB2-mediated mechanisms. It further enables dissection of lipid metabolic reprogramming in HPV-driven cancers and evaluation of potential crosstalk with viral oncoproteins.
Typical applications include drug target validation, high-throughput screening of ABHD6 inhibitors, functional genomics of serine hydrolases, and mechanistic studies of endocannabinoid signaling in cervical cancer. Researchers can employ a range of assays: Western blot and RT-qPCR for ABHD6 expression; LC-MS-based quantification of 2-AG; CB1/CB2 activity measurements; cell proliferation (MTT, BrdU), migration, and invasion assays; apoptosis detection; RNA sequencing for transcriptomic profiling; and phospho-signaling analysis. For further information or technical support, please contact Ascent Research.
